Invitae announced the availability of its Detect programs to provide no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment. Research has shown no-charge testing programs result in earlier diagnosis and treatment. Enrollment is now open for Detect programs in four conditions: muscular dystrophy, prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
